Home / Europe / Netherlands / Life Sciences & Healthcare

Life Sciences & Healthcare

Our dedicated Life Sciences & Healthcare team specialises in advising clients in the pharmaceutical, medical devices, cosmetics, novel food and agriculture industry. ​

We have extensive experience in serving our clients, who represent 80% of the leading industry players. Because many of us have in-house experience, we understand your unique challenges and needs and have the ability to provide you with hands-on commercial advice.​

Our team operates across all relevant legal disciplines involved in supporting this sector. This includes industry specific regulatory and compliance work, intellectual property matters and competition law advice. We also advise on commercial, data privacy, employment, real estate and corporate matters. Our expertise allows us to meet both local and international business needs of our clients.

Their litigation abilities are excellent, with in-firm expertise available on related legal topics.

The Legal500 EMEA, 2022

Clients particularly value the team's commercial awareness, praising their "good insights into what is going on in the pharmaceutical market in the Netherlands."

Chambers Europe, 2022

The team is recommended for its "specific knowledge regarding tenders and projects in the field of medical appliances."

Chambers Europe 2021

The firm has "an excellent knowledge of pharmaceutical regulations and a practical mindset."

Chambers Europe 2021

‘Speedy responses and practical advice in pharma and corporate law matters.’

The Legal 500 EMEA, 2020

"really brilliant" , "broad network" and that the firm "co-ordinates things well".

Chambers Europe-wide, 2020

"Really efficient and quick."

Chambers Global, 2020

"The firm is a reliable international firm that has shown us a deep knowledge of the applicable law and significant practical experience on relevant cases."

Chambers Global, 2020

Choose area

With technology and digital innovation at the forefront of many advancements in the life sciences industry and healthcare delivery, companies are cons
Medical Devices and Diagnostics
Medical devices and diagnostics are quickly evolving, integrating innovative tech solutions that use and generate increasing amounts of data. They hav
Novel Food (incl. Cannabis/CBD)
An ever increasing awareness of climate change and the need to modify our behaviour to address it, is leading to a huge demand for more sustainable –
microscope with bottles of chemicals in forefront
In the last decade, it has become increasingly complex and costly to obtain marketing authorisation. On top of this,  market access has become   more
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With big deals fuel­ling re­cord levels of M&A activ­ity, a steady stream of in­nov­at­ive and dis­rupt­ive tech­no­lo­gies, new and in­creas­ingly com­plex reg­u­lat­ory chal­lenges and a thriv­ing start-up com­munity...
Sub­scribe to Life Sci­ences & Health­care top­ics


What is the sig­ni­fic­ance of a clin­ic­al tri­al pro­tocol as pri­or art at the...
The EPO Ap­peal Board has fur­ther re­fined their view on when pri­or art dis­clos­ures of clin­ic­al tri­al pro­to­cols are an is­sue for pat­entab­il­ity of med­ic­al use claims. De­cision T1806/18 In de­cision T1806/18...
Glob­al Life Sci­ences & Health­care For­um 2022: Fa­cing the op­por­tun­it­ies...
Di­git­al ad­vances and in­nov­at­ive ther­apies are push­ing the bound­ar­ies of health and the leg­al world has to keep pace Life sci­ences are fizz­ing with in­genu­ity and in­nov­a­tion with re­volu­tion­ary gene and...
EU Com­mis­sion pro­poses to mod­ern­ise product li­ab­il­ity rules for green and...
Cur­rent product li­ab­il­ity rules, based on the 85/374/EGK Product Li­ab­il­ity Dir­ect­ive (PLD), are nearly 40 years old and no longer suit­able for the mod­ern di­git­al age. Among oth­er things, the PLD is un­cer­tain...
Glob­al Life Sci­ences & Health­care For­um 2022: Life Sci­ences are reap­ing...
Di­git­al trans­form­a­tion in life sci­ences is cre­at­ing op­por­tun­it­ies to counter health­care’s most in­tract­able prob­lems from treat­ing rare dis­eases to ac­cel­er­at­ing dia­gnostics and re­du­cing treat­ment back­logs...
Glob­al Life Sci­ences & Health­care For­um 2022: The Life Sci­ences sec­tor...
The open­ing of COP27 has brought an in­tense glob­al fo­cus on cli­mate change and the tower­ing de­mands needed to reach car­bon net zero and to pro­tect the en­vir­on­ment. United Na­tions Gen­er­al Sec­ret­ary Ant­o­nio...
Glob­al Life Sci­ences & Health­care For­um 2022: The leg­al sec­tor has a key...
The United Na­tions has pledged to use its pur­chas­ing fire­power to ac­cel­er­ate sus­tain­ab­il­ity along the health­care sup­ply chan­nel and called on the leg­al sec­tor to sup­port its ef­forts. Law­yers are crit­ic­al...
Skin­teg­rated Cos­me­ceut­ic­als - is Pharma be­com­ing sexy (again?)
Case Study: Skin­tegra, Skin­teg­rity Cos­me­ceut­ic­als are sexy right now.  They’re less reg­u­lated than the phar­ma­ceut­ic­al in­dustry (al­though don’t let that fool you in­to be­liev­ing you can say whatever...
Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? 1.1 Medi­cines The Medi­cines Act is the primary law on ad­vert­ising of medi­cines. In ad­di­tion, the Dutch Civil Code...
UPC Rules of Pro­ced­ure go in­to force with judg­ments to be made pub­lic
The entry in­to force of the Rules of Pro­ced­ure is part of the fi­nal pre­par­a­tions for the United Pat­ent Court (UPC), which is cur­rently ex­pec­ted to start work in early 2023. After the bod­ies of the UPC...
Can­nabis law and le­gis­la­tion in the Neth­er­lands
Med­ic­al use The Dutch Opi­um Act dis­tin­guishes drugs with a low risk of harm (‘soft drugs’) from drugs with a high risk of harm (‘hard drugs’). Can­nabis is lis­ted un­der the soft drugs cat­egory...
Phar­ma­ceut­ic­al trade marks - a real pain in the bum?
An EU IPO Case Study: Proc­to­LYSY­AL v PRO­COTOL­IZ­IN Sum­mary I al­ways like to start at the end.  No nasty sur­prises and you know what to ex­pect.  In this case study, the trade marks ‘proc­to­LYSY­AL’...
Leg­al is­sues in the meta­verse / Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial...
Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial In­tel­li­gence Reg­u­la­tion, the meta­verse as a work­place In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world. The emer­gence...